Photocure ASA (PHOO.XC)
| Previous close | 57.70 |
| Open | 56.70 |
| Bid | 56.80 x N/A |
| Ask | 59.10 x N/A |
| Day's range | 57.70 - 57.70 |
| 52-week range | 56.70 - 98.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.756B |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.24 |
| Earnings date | 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 26 Nov 2009 |
| 1y target est | N/A |
PR NewswirePhotocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.
Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced activities to support a new initiative enabling U.S. Hospitals and Clinics to offer blue light cystoscopy (BLC®) using a mobile capital equipment model. The initiative is aligned with a recently executed agreement between Karl Storz and ForTec Medical, aimed at providing on-demand Saphira™ BLC equipment to hospitals in the U.S. leveraging ForTec's utilization-driven mobile equipment business model.
PR NewswirePhotocure ASA - Annual general meeting held
Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST).
PR NewswirePhotocure ASA: Results for the first quarter of 2024
Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding b
